Inhibition of mitotic a aurora kinase a by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI -N78 cells

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 487-508

  Yuan, Chun Xiu ^a,b   Zhou, Zhi Wei ^b,c   Yang, Yin Xue ^a   He, Zhi Xu ^c   Zhang, Xueji ^d   Wang, Dong ^e   Yang, Tianxing ^f   Wang, Ning Ju ^a   Zhao, Ruan Jin ^g   Zhou, Shu Feng ^b  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Center for Traditional Chinese Medicine   (United States)

Author keywords

Alisertib; Apoptosis; AURKA; Autophagy; Gastric cancer

Indexed keywords

ALISERTIB; AURORA A KINASE; CASPASE 3; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOCHROME C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; WORTMANNIN; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; AZEPINE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

AGS CELL LINE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE MICROSCOPY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; NCI N78 CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; G2 PHASE CELL CYCLE CHECKPOINT; METABOLISM; MITOSIS; PATHOLOGY; PHOSPHORYLATION; STOMACH TUMOR; TIME FACTOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AURORA KINASE A; AUTOPHAGY; AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MITOSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84921516623     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S74127     Document Type: Article

References (62)

1. GLOBOCAN 2012: Cancer Incidence and Mortality Worldwide in 2012 [webpage on the Internet]. Lyon: International Agency for Research on Cancer, World Health Organization; 2014. Available from: http://globocan.iarc.fr. Accessed November 10, 2014.
2. Wang J, Yang S, Zhang H, et al. Aurora-A as an independent molecular prognostic marker in gastric cancer. OncolRep. 2011;26(1):23-32.
3. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362(9380):305-315.
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
5. Bolanos-Garcia VM. Aurora kinases. Int J Biochem Cell Biol. 2005;37(8):1572-1577.
6. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci. 2007;120(Pt 17):2987-2996.
7. Huck JJ, Zhang M, McDonald A, et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res. 2010;8(3):373-384.
8. Görgün G, Calabrese E, Hideshima T, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115(25):5202-5213.
9. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther. 2010;9(2):268-278.
10. Sehdev V, Peng D, Soutto M, et al. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther. 2012;11(3):763-774.
11. Rugge M, Fassan M, Zaninotto G, et al. Aurora kinase A in Barrett's carcinogenesis. Hum Pathol. 2010;41(10):1380-1386.
12. Cammareri P, Scopelliti A, Todaro M, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010;70(11):4655-4665.
13. Manfredi MG, Ecsedy JA, Chakravarty A, et al. Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res. 2011;17(24):7614-7624.
14. Carol H, Boehm I, Reynolds CP, et al. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 2011;68(5):1291-1304.
15. Barranco SC, Townsend CM Jr, Quraishi MA. Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs. Invest New Drugs. 1983;1(2):117-127.
16. Park JG, Frucht H, LaRocca RV. Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 1990;50(9):2773-2780.
17. Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014;344(2):239-259.
18. Qiu JY, Zhou ZW, He ZX, et al. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial to mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. Drug Des Devel Ther. In press.
19. Stupack DG. Caspase-8 as a therapeutic target in cancer. Cancer Lett. 2013;332(2):133-140.
20. Balan M, Pal S. A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem. 2014;289(6):3126-3137.
21. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25(1):52-58.
22. Carvajal LA, Manfredi JJ. Another fork in the road - life or death decisions by the tumour suppressor p53. EMBO Rep. 2013;14(5):414-421.
23. Yoon MK, Mitrea DM, Ou L, Kriwacki RW. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans. 2012;40(5):981-988.
24. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231-241.
25. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717-1721.
26. Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ. 2012;19(1):87-95.
27. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813(11):1978-1986.
28. Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330(6009):1344-1348.
29. Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet. 2013;163C(2):114-121.
30. Dunlop EA, Tee AR. The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis. Biochem Soc Trans. 2013;41(4):939-943.
31. Kim J, Guan KL. Regulation of the autophagy initiating kinase ULK1 by nutrients: roles of mTORC1 and AMPK. Cell Cycle. 2011;10(9):1337-1338.
32. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13(9):679-692.
33. Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4(9-10):342-359.
34. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571-580.
35. Maiuri MC, Criollo A, Kroemer G. Crosstalk between apoptosis and autophagy within the Beclin 1 interactome. EMBO J. 2010;29(3):515-516.
36. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720-5728.
37. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-1657.
38. Dar AA, Belkhiri A, El-Rifai W. The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene. 2009;28(6):866-875.
39. Kubota E, Kataoka H, Tanaka M, et al. ERas enhances resistance to CPT-11 in gastric cancer. Anticancer Res. 2011;31(10):3353-3360.
40. Hildebrandt MA, Yang H, Hung MC, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009;27(6):857-871.
41. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res. 2006;12(23):6869-6875.
42. Hilton JF, Shapiro GI. Aurora kinase inhibition as an anticancer strategy. J Clin Oncol. 2014;32(1):57-59.
43. Mountzios G, Terpos E, Dimopoulos MA. Aurora kinases as targets for cancer therapy. Cancer Treat Rev. 2008;34(2):175-182.
44. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012;30(6):2411-2432.
45. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 2010;55(1):26-34.
46. Tomita M, Mori N. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci. 2010;101(5):1204-1211.
47. Baldin V, Ducommun B. Subcellular localisation of human wee1 kinase is regulated during the cell cycle. J Cell Sci. 1995;108(Pt 6):2425-2432.
48. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science. 1997;277(5331):1501-1505.
49. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88(11):2619-2628.
50. Qin L, Tong T, Song Y, Xue L, Fan F, Zhan Q. Aurora-A interacts with Cyclin B1 and enhances its stability. Cancer Lett. 2009;275(1):77-85.
51. Dar AA, Zaika A, Piazuelo MB, et al. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer. 2008;112(8):1688-1698.
52. Sehdev V, Katsha A, Arras J, et al. HDM2 regulation by AURKA promotes cell survival in gastric cancer. Clin Cancer Res. 2014;20(1):76-86.
53. Katsha A, Soutto M, Sehdev V, et al. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology. 2013;145(6):1312-1322.e1-8.
54. Katsha A, Arras J, Soutto M, Belkhiri A, El-Rifai W. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. Mol Oncol. Epub 2014 Jun 3.
55. Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487-498.
56. Reyjal J, Cormier K, Turcotte S. Autophagy and cell death to target cancer cells: exploiting synthetic lethality as cancer therapies. Adv Exp Med Biol. 2014;772:167-188.
57. Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845.
58. Estaquier J, Vallette F, Vayssiere JL, Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012;942:157-183.
59. Chen Y, Yu L. Autophagic lysosome reformation. Exp Cell Res. 2013;319(2):142-146.
60. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143-153.
61. Yao JE, Yan M, Guan Z, et al. Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer. 2009;8:95.
62. Long M, Hao M, Dong K, et al. AEG-1 overexpression is essential for maintenance of malignant state in human AML cells via up-regulation of Akt1 mediated by AURKA activation. Cell Signal. 2013;25(6):1438-1446.